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The use of methylene blue and toluidine blue in the photodynamic treatment of onychomycosis at 
an ambulatory clinic in São Paulo, Brazil is reported.  Local application and illumination of infected 
nails produced a response in 53 of 62 patients, without any pain or burning associated with the 
therapy. 
 





Among infectious diseases, external fungal infections in the non-immunocompromised host are 
generally treated as insignificant. While visible lesions, e.g. of the hands or face, might require 
treatment on the basis of cosmesis, those of the feet – at least in temperate climes – are likely to be 
mainly hidden by clothing and are consequently often ignored.  Non-intervention against 
dermatophytic fungi, such as the Trichophyton spp involved in Athlete’s Foot, allows fungal spread 
and consequent invasion of the nail bed (onychomycosis).  Whereas infection of the dermis is 
normally susceptible to conventional antifungal therapy, either topically or systemically 
administered, nail bed infection represents a difficult presentation for such topical approach and 
often requires recourse to extended systemic administration of azole or allylamine drugs [1].  
From previous in vitro work, it is clear that cationic photosensitising agents, such as the established 
methylene blue derivatives, offer a rapid fungicidal effect, due to the production of reactive oxygen 
species (e.g. singlet oxygen) on illumination [2].  In addition, methylene blue itself and other 
phenothiazinium derivatives, e.g. toluidine blue, have established low toxicities in the human host 
[3].  This combination therefore suggests a potential therapeutic approach to the topical treatment 
of recalcitrant fungal infection, such as that presented in onychomycosis. 
The following report describes a recent and ongoing small-scale trial of the use of methylene blue 
and toluidine blue in combination as an alternative to the conventional treatment of fungal nail bed 
infection in patients in a São Paulo clinic.  It should be noted that this was not intended as a properly 
controlled clinical trial involving controls and placebos.  The treatment was offered as an alternative 
to conventional chemotherapeutics for patients presenting with onychomycosis. 
 
2. Materials and Methods 
 
2.1 Photosensitiser preparation 
Solutions of methylene blue (MB) and toluidine blue (TB) (Labsynth Laboratory Suppliers, São Paulo, 
Brazil) were prepared at 2% (w/v) in 10% aqueous ethanol (v/v). 
 
2.2 Light irradiation 
The in-house light source RL50® [4] was employed. This emits light in the red region of the spectrum 
from 600-750 nm and overlaps well with the MB/TB action spectra.  It delivers 100mW/cm2 at a 
distance of 5 cm from the source. 
 
2.3 Patients 
Patients with onychomycosis were treated in the Dermatology Service of the School of Medicine of 
ABC, São Paulo, as a free public service. Informed consent was obtained from the patients. 
 2.4 Protocol 
Infected nails were photographed before treatment.  The nail bed was cleaned after scraping the 
nail surface with a sharp curette and the material removed was sent for microbiological analysis. A 
1:1 volume of the 2% methylene blue / 2% toluidine blue mixture was then applied between the nail 
plate and nail bed. After 5 minutes the nail was irradiated superficially with the RL50 source at a 
distance of 5 cm for 3 minutes, providing a final irradiance of 18 J/cm2.  The site was assessed and 
photographed after a period of 30 days, when the protocol was repeated if necessary. 
 
3. Results and Discussion 
Microbiological analysis of the initial nail curettage showed that the infections were caused (singly) 
by the common fungi Trichophyton rubrum, T. mentagrophytis or Candida albicans.  The authors 
have reported the successful photodynamic eradication of these organisms previously in vitro, using 
MB, TB and related phenothiazinium derivatives as the photosensitising agents [5,6]. 
From Table 1 it can be seen that 28/62 patients completing the treatment exhibited complete 
clearance of fungal nail infection (Figure 1), with 25/62 partial clearances. 
 
Outcome n % 
Complete clearance 28 45 
Partial clearance 25 40 
No change 9 15 
 




Figure 1. Complete clearance of nailbed infection after photodynamic treatment. 
 
The data in Table 1 represent the initial results from an ongoing treatment protocol carried out in 
São Paulo since 2000, with the number of sessions varying with the severity of disease and speed of 
nail growth.  As noted, 62 patients were considered to have completed therapy.  Treatments often 
covered multiple visits and several patients dropped out due to dislike of the blue coloration of the 
nail and peripheral tissues (Figure 2). The number of sessions ranged from 1 to 22, and sessions 
occurred once a month.  The average number of treatments for complete clearance was five (5.22) 
and some of the patients showing partial clearance are still under treatment.  However, of those 
treated, none reported any pain, burning or discomfort during the illumination period, in contrast to 
other local photodynamic anti-infective approaches: for example, the treatment of acne vulgaris 
using aminolaevulinic acid [7]. Patients in the present cohort had generally tried to cure their 
infections previously using conventional antifungal agents, such as ketoconazole or terbinafine.  
However, there was no direct evidence to suggest that the causative organisms were of 
conventional-drug resistant strains.  Theoretically at least, and in agreement with in vitro reports, 
the conventional drug-susceptibility of the invading organism should have no influence on the 





Figure 2. Application of methylene blue/toluidine blue, showing staining of peripheral tissue. 
 
The photodynamic approach to the treatment of fungal disease contrasts strongly with those 
employing conventional agents.  Firstly, at present, medical supervision is required to oversee the 
application of both the photosensitiser and light to the infected area. However, the photodynamic 
approach might require only single application.  This is clearly not the case with conventional 
therapeutics: although oral antifungal therapy must be prescribed and thus requires the 
involvement of medical personnel, administrative regimens are often extensive and prolonged, 
requiring up to sixteen weeks’ oral administration. In addition, significant side effects have been 
reported during terbinafine self-administration, including liver damage, taste and smell disturbances 
and depressive symptoms [9]. 
The authors have reported the use of the methylene blue approach also for the treatment of herpes 
simplex lesions, which again exhibited ease of use, absence of pain/burning and excellent cosmesis 
[10].  Since the general method has no apparent negative sequelae, repeat applications might be 
made by the patient, although this would presumably require a metred light source.  It is expected 
that relatively simple localised infections of this type would be amenable to the photodynamic 
approach in future, in order to conserve valuable conventional antimicrobial agents. 
 
4. Conclusion 
Given the widespread therapeutic problems and increased healthcare expenditure due to microbial 
drug resistance, it is sensible to examine novel, non-conventional approaches to infection control.  
Clinical photodynamic antimicrobial chemotherapy, such as that described here, offers effective 
antifungal capability against a target which normally requires considerable effort on the part of the 
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